ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to "Hold" at StockNews.com

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) was upgraded by stock analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued on Wednesday.

Several other research analysts have also weighed in on ANIP. Guggenheim reaffirmed a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective for the company. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $80.13.

ANI Pharmaceuticals Trading Down 0.7 %

ANI Pharmaceuticals stock traded down $0.46 during trading on Wednesday, reaching $68.75. 54,048 shares of the company were exchanged, compared to its average volume of 270,593. The stock's 50 day simple moving average is $63.26 and its two-hundred day simple moving average is $59.46. The company has a market capitalization of $1.50 billion, a P/E ratio of -125.00 and a beta of 0.49. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $70.48.

Insider Activity

In other news, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the transaction, the senior vice president now owns 68,624 shares of the company's stock, valued at $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Meredith Cook sold 400 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock worth $197,792 over the last ninety days. 12.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ANIP. HighTower Advisors LLC acquired a new position in ANI Pharmaceuticals in the third quarter valued at $222,000. Stifel Financial Corp acquired a new stake in ANI Pharmaceuticals during the 3rd quarter valued at approximately $418,000. State Street Corp grew its position in shares of ANI Pharmaceuticals by 9.1% during the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company's stock worth $41,991,000 after buying an additional 58,698 shares in the last quarter. Barclays PLC increased its position in shares of ANI Pharmaceuticals by 1,681.2% in the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock worth $8,534,000 after purchasing an additional 135,003 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in ANI Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company's stock valued at $25,373,000 after buying an additional 17,314 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.